Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
about
BRCA Genetic Testing and Receipt of Preventive Interventions Among Women Aged 18-64 Years with Employer-Sponsored Health Insurance in Nonmetropolitan and Metropolitan Areas - United States, 2009-2014.Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors.PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype.Breast cancer: The translation of big genomic data to cancer precision medicine.Emerging treatment options for ovarian cancer: focus on rucaparib.Update Breast Cancer 2017 - Implementation of Novel Therapies.The OlympiAD trial: who won the gold?Targeted therapy for metastatic triple negative breast cancer: The next frontier in precision oncology.Development and cytotoxic response of two proliferative MDA-MB-231 and non-proliferative SUM1315 three-dimensional cell culture models of triple-negative basal-like breast cancer cell lines.De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.The development of PARP as a successful target for cancer therapy.Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution.New agents for the management of resistant metastatic breast cancer.Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.Predictors of survival for breast cancer patients with a BRCA1 mutation.Breast cancer in 2017: Spurring science, marking progress, and influencing history.Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform.Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer with Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02).Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness.PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi."Lazarus Response" to Olaparib in a Virtually Chemonaive Breast Cancer Patient Carrying Gross BRCA2 Gene Deletion.RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA mutated breast cancer.PARP inhibitors for homologous recombination-deficient prostate cancer.Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention.Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer.Interference with DNA repair after ionizing radiation by a pyrrole-imidazole polyamide.Major clinical research advances in gynecologic cancer in 2017.How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies.Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: results of monotherapy and combination therapy trials.Advances in the systemic treatment of triple-negative breast cancer.Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer.Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies.Progress in breast cancer-can we do better?Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis.An 18F-Labeled Poly(ADP-ribose) Polymerase Positron Emission Tomography Imaging Agent.Synthetic Lethality-based Identification of Targets for Anticancer Drugs in the Human Signaling Network.Recent Advances in the Treatment of Breast Cancer.Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.
P2860
Q40053882-40A59E95-AAE5-4167-A2AC-D24340773D84Q41552673-5BA89117-15DB-4C65-AF13-6CDB145C644BQ42517340-34CFF0BC-05C2-465B-83E3-6324E20557E4Q42700663-E99B4EF7-75C7-452A-B031-93C50CBDD7B7Q45943221-C660DCA8-AA93-4B23-8F70-658367606566Q47107471-7E769101-17DE-42ED-8171-800FAFE6FEDCQ47110841-A0A11FB3-FA4E-48C7-A309-620124678BC7Q47132052-D311A7E7-27F5-48F5-BDE8-9C834E9D9FD2Q47147831-AABE3F80-0C04-49D8-9D6B-30C5FD9DB464Q47164952-E008A8F4-8B9D-4C15-8949-529370936789Q47232243-73C3AFAF-368B-4C86-922A-B21F32D16EA6Q47278103-664B02F3-90F4-47EB-AE80-82CDA9FF8BB3Q48157533-5D21B4F6-AC60-4BA4-847F-1D130FB48281Q48240854-2E9B2A4A-9864-407D-8222-451184425251Q48263612-4D380AA7-EBF2-487D-B759-4F311B607965Q49787762-2DF2154D-6F5C-4023-94E9-8B7BE37A1F08Q49907753-4DE839DC-6880-4CAA-96DE-73DD2A2394B3Q50099775-2701FAFF-28D3-4BE1-BD99-205722FEC121Q50127275-76A08628-D164-4773-83B4-32CBF79916B3Q50193922-7BF9EAD6-C627-4C44-BE94-8231BEE08939Q52585367-64129C7F-5688-417E-9920-28900035771DQ52590685-53967D37-63B3-421C-B051-ED9F7AA40E9AQ52590701-FF4D60AB-C86C-4124-9D53-0C50C29CA8ADQ52596087-771C3D3D-0AAE-4069-B1FA-263AF8280398Q52623144-5E92F493-98F5-4DC0-B26E-807266DE16F2Q52632715-A803823C-E6DF-4F3C-A8DC-2F616FDC0C7AQ52660922-869EACEE-BD61-4A87-8228-DFEF2773FF50Q52715168-474E04DA-367B-4CF5-9A51-ED70D4D703CEQ54952356-08413E47-2E1C-404B-8E76-12805EF85FB4Q54965602-CD29C010-2A9A-4E6A-B2F1-917AE2B4E2BDQ55044880-D5B77029-28EC-4402-83BA-3DC24D136EE5Q55105639-6DD65AC8-D171-46DA-B7AD-7260D47CCD18Q55211683-7D68AC3A-4B4C-4D57-B95C-E7BDE59FD46BQ55287222-E37DC603-4A5E-424A-B74E-39D2F0A1D0B0Q55288231-34910AF5-28E5-4A8A-B998-F5C3816579BDQ55309832-038B6251-8836-4B3F-8A19-EEDC37D7B2EBQ55326030-BDCD2690-A5EF-4ADC-8B7D-16E1DA584344Q55343692-4936AB24-FFE1-436B-A4BD-C72FFA1B5F26Q55353691-9A7EB585-1E39-4E8E-9D91-642E1062492CQ55381932-85684474-33F9-4D81-8CB7-D25D65038209
P2860
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
@en
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
@nl
type
label
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
@en
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
@nl
prefLabel
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
@en
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
@nl
P2093
P50
P356
P1476
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
@en
P2093
Anne Armstrong
Carsten Goessl
Elżbieta Senkus
Nadine Tung
Norikazu Masuda
Pierfranco Conte
Sarah Runswick
Seock-Ah Im
Suzette Delaloge
P304
P356
10.1056/NEJMOA1706450
P407
P577
2017-06-04T00:00:00Z